vs
Side-by-side financial comparison of IOVANCE BIOTHERAPEUTICS, INC. (IOVA) and Life360, Inc. (LIF). Click either name above to swap in a different company.
Life360, Inc. is the larger business by last-quarter revenue ($146.0M vs $86.8M, roughly 1.7× IOVANCE BIOTHERAPEUTICS, INC.). On growth, Life360, Inc. posted the faster year-over-year revenue change (26.4% vs 17.7%). Life360, Inc. produced more free cash flow last quarter ($36.6M vs $-61.9M). Over the past eight quarters, IOVANCE BIOTHERAPEUTICS, INC.'s revenue compounded faster (1001.6% CAGR vs 36.6%).
Iovance Biotherapeutics, Inc. is a biopharmaceutical startup based in San Carlos, California. The company works to develop tumor-infiltrating lymphocyte (TIL) therapies against cancer.
Life360, Inc. develops family-focused safety and connectivity platforms. Core offerings include real-time location sharing, emergency alerts, driving behavior analysis tools and identity theft protection. It serves consumer markets across North America, Europe and Asia-Pacific, with most revenue from tiered premium subscription plans.
IOVA vs LIF — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $86.8M | $146.0M |
| Net Profit | — | $129.7M |
| Gross Margin | 67.4% | 75.1% |
| Operating Margin | -84.7% | 6.1% |
| Net Margin | — | 88.8% |
| Revenue YoY | 17.7% | 26.4% |
| Net Profit YoY | — | 1425.9% |
| EPS (diluted) | — | $1.53 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $86.8M | $146.0M | ||
| Q3 25 | $67.5M | $124.5M | ||
| Q2 25 | $60.0M | $115.4M | ||
| Q1 25 | $49.3M | $103.6M | ||
| Q4 24 | $73.7M | $115.5M | ||
| Q3 24 | $58.6M | $92.9M | ||
| Q2 24 | $31.1M | $84.9M | ||
| Q1 24 | $715.0K | $78.2M |
| Q4 25 | — | $129.7M | ||
| Q3 25 | $-91.3M | $9.8M | ||
| Q2 25 | $-111.7M | $7.0M | ||
| Q1 25 | $-116.2M | $4.4M | ||
| Q4 24 | — | $8.5M | ||
| Q3 24 | $-83.5M | $7.7M | ||
| Q2 24 | $-97.1M | $-11.0M | ||
| Q1 24 | $-113.0M | $-9.8M |
| Q4 25 | 67.4% | 75.1% | ||
| Q3 25 | 43.0% | 78.0% | ||
| Q2 25 | 5.5% | 78.4% | ||
| Q1 25 | -0.8% | 80.6% | ||
| Q4 24 | 68.7% | 74.0% | ||
| Q3 24 | 46.2% | 75.4% | ||
| Q2 24 | -0.8% | 75.0% | ||
| Q1 24 | — | 76.7% |
| Q4 25 | -84.7% | 6.1% | ||
| Q3 25 | -140.7% | 4.6% | ||
| Q2 25 | -189.8% | 1.7% | ||
| Q1 25 | -245.8% | 2.1% | ||
| Q4 24 | -117.5% | 4.9% | ||
| Q3 24 | -152.1% | -5.3% | ||
| Q2 24 | -327.6% | -2.8% | ||
| Q1 24 | -16464.6% | -8.2% |
| Q4 25 | — | 88.8% | ||
| Q3 25 | -135.3% | 7.9% | ||
| Q2 25 | -186.2% | 6.1% | ||
| Q1 25 | -235.5% | 4.2% | ||
| Q4 24 | — | 7.4% | ||
| Q3 24 | -142.7% | 8.3% | ||
| Q2 24 | -312.2% | -12.9% | ||
| Q1 24 | -15800.8% | -12.5% |
| Q4 25 | — | $1.53 | ||
| Q3 25 | — | $0.11 | ||
| Q2 25 | $-0.33 | $0.08 | ||
| Q1 25 | $-0.36 | $0.05 | ||
| Q4 24 | $-0.24 | $0.14 | ||
| Q3 24 | $-0.28 | $0.09 | ||
| Q2 24 | $-0.34 | $-0.15 | ||
| Q1 24 | $-0.42 | $-0.14 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $297.0M | $494.3M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $698.6M | $548.2M |
| Total Assets | $913.2M | $959.7M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $297.0M | $494.3M | ||
| Q3 25 | $300.8M | $455.7M | ||
| Q2 25 | $301.2M | $432.7M | ||
| Q1 25 | $359.7M | $168.9M | ||
| Q4 24 | $323.8M | $159.2M | ||
| Q3 24 | $397.5M | $159.0M | ||
| Q2 24 | $412.5M | $160.8M | ||
| Q1 24 | $356.2M | $73.4M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | $5.2M |
| Q4 25 | $698.6M | $548.2M | ||
| Q3 25 | $702.3M | $391.4M | ||
| Q2 25 | $698.5M | $366.7M | ||
| Q1 25 | $767.9M | $376.3M | ||
| Q4 24 | $710.4M | $358.5M | ||
| Q3 24 | $773.5M | $339.7M | ||
| Q2 24 | $768.5M | $326.7M | ||
| Q1 24 | $680.0M | $239.8M |
| Q4 25 | $913.2M | $959.7M | ||
| Q3 25 | $904.9M | $787.5M | ||
| Q2 25 | $907.4M | $753.6M | ||
| Q1 25 | $966.7M | $455.4M | ||
| Q4 24 | $910.4M | $441.6M | ||
| Q3 24 | $991.1M | $427.4M | ||
| Q2 24 | $964.3M | $405.9M | ||
| Q1 24 | $869.8M | $318.8M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | 0.02× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-52.6M | $36.8M |
| Free Cash FlowOCF − Capex | $-61.9M | $36.6M |
| FCF MarginFCF / Revenue | -71.3% | 25.1% |
| Capex IntensityCapex / Revenue | 10.7% | 0.2% |
| Cash ConversionOCF / Net Profit | — | 0.28× |
| TTM Free Cash FlowTrailing 4 quarters | $-336.2M | $86.8M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-52.6M | $36.8M | ||
| Q3 25 | $-78.7M | $26.4M | ||
| Q2 25 | $-67.4M | $13.3M | ||
| Q1 25 | $-103.7M | $12.1M | ||
| Q4 24 | $-73.3M | $12.3M | ||
| Q3 24 | $-59.0M | $6.3M | ||
| Q2 24 | $-98.4M | $3.3M | ||
| Q1 24 | $-122.3M | $10.7M |
| Q4 25 | $-61.9M | $36.6M | ||
| Q3 25 | $-89.5M | $25.6M | ||
| Q2 25 | $-74.9M | $12.7M | ||
| Q1 25 | $-109.9M | $11.9M | ||
| Q4 24 | $-77.5M | $11.2M | ||
| Q3 24 | $-61.3M | $6.3M | ||
| Q2 24 | $-98.9M | $3.2M | ||
| Q1 24 | $-126.5M | — |
| Q4 25 | -71.3% | 25.1% | ||
| Q3 25 | -132.7% | 20.6% | ||
| Q2 25 | -124.9% | 11.0% | ||
| Q1 25 | -222.8% | 11.5% | ||
| Q4 24 | -105.1% | 9.7% | ||
| Q3 24 | -104.6% | 6.8% | ||
| Q2 24 | -317.9% | 3.8% | ||
| Q1 24 | -17685.3% | — |
| Q4 25 | 10.7% | 0.2% | ||
| Q3 25 | 16.1% | 0.6% | ||
| Q2 25 | 12.4% | 0.6% | ||
| Q1 25 | 12.6% | 0.1% | ||
| Q4 24 | 5.7% | 1.0% | ||
| Q3 24 | 3.9% | 0.0% | ||
| Q2 24 | 1.4% | 0.1% | ||
| Q1 24 | 583.4% | 0.0% |
| Q4 25 | — | 0.28× | ||
| Q3 25 | — | 2.70× | ||
| Q2 25 | — | 1.90× | ||
| Q1 25 | — | 2.75× | ||
| Q4 24 | — | 1.45× | ||
| Q3 24 | — | 0.83× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
IOVA
| Amtagvi | $64.9M | 75% |
| Proleukin | $21.9M | 25% |
LIF
Segment breakdown not available.
